Each week, Valens focuses on several companies that were analyzed in the prior week, where material distortions caused by as-reported GAAP accounting need to be corrected to understand a company’s economic fundamentals.
Company Specific Highlights & Insights
Teva Pharmaceutical Industries Limited (TEVA)
R&D Expense Distortion
Palo Alto Networks, Inc. (PANW)
Stock Option Expense Distortion
Valeant Pharmaceuticals International, Inc. (VRX)
Gross Cash Flow Acquisition Adjustment